Over the past 12‑18 months the Casein Glycomacropeptide industry trends have accelerated through a series of strategic moves. In March 2024, dairy‑technology leader Arla Foods formed a partnership with biotech start‑up GlycoPure to co‑develop a low‑phenylalanine CGMP isolate for medical nutrition, leveraging GlycoPure’s enzymatic purification platform. The same quarter, Danone acquired the U.S. specialty ingredient firm NutriMolecule for $210 million, expanding its portfolio of CGMP‑based functional powders. In July 2024, FrieslandCampina launched a patented “CGMP‑Boost” micro‑encapsulation technology that improves solubility and stability in plant‑based beverages, sparking early adoption by several beverage manufacturers. Regulatory momentum arrived in September 2024 when the European Food Safety Authority updated its novel food guidance, explicitly recognizing CGMP as safe for infant formula, opening new market channels. Meanwhile, consumer demand for clean‑label, low‑allergen protein has driven a 22 % YoY rise in CGMP sales, prompting major dairy processors to repurpose excess whey streams. Finally, a $45 million Series B round closed for Swiss start‑up ProBioCGMP, funding a new pilot plant slated for early 2025, underscoring confidence in the segment’s growth trajectory.
